LivingGLP1
Study S001638

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Registration

Registration
NCT00744926
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
373
Start
2008-08
Primary completion
2010-04
Lead sponsor
Hoffmann-La Roche
Conditions
Diabetes Mellitus Type 2
Interventions
DRUG:placebo; DRUG:taspoglutide
Results posted
FALSE
Secondary identifiers
OTHER:2008-001765-28; NIH:2008

Registered primary outcomes

  • Absolute change from baseline in HbA1c [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.